{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:48:47Z","timestamp":1786996127539,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2023R1A2C3003782"],"award-info":[{"award-number":["2023R1A2C3003782"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016275","name":"Seoul National University Bundang Hospital","doi-asserted-by":"publisher","award":["14\\u20132023-0004"],"award-info":[{"award-number":["14\\u20132023-0004"]}],"id":[{"id":"10.13039\/100016275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.radonc.2025.110932","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T13:39:17Z","timestamp":1746970757000},"page":"110932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["TIGIT blockade increases efficacy of PD-1 blockade combined with radiation therapy in triple-negative breast cancer model"],"prefix":"10.1016","volume":"208","author":[{"given":"Seongmin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hyuck","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoomin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110932_b0005","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.radonc.2025.110932_b0010","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.110932_b0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance Mechanisms to Anti-PD Cancer Immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.radonc.2025.110932_b0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: A beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.radonc.2025.110932_b0025","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138740","article-title":"Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control","volume":"131","author":"Lhuillier","year":"2021","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.radonc.2025.110932_b0030","doi-asserted-by":"crossref","first-page":"16691","DOI":"10.3390\/ijms242316691","article-title":"Modulation of CD8+ T Cell Responses by Radiotherapy\u2014Current Evidence and Rationale for Combination with Immune Checkpoint Inhibitors","volume":"24","author":"Jeon","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.radonc.2025.110932_b0035","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4049\/jimmunol.1200563","article-title":"Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation","volume":"189","author":"Gupta","year":"2012","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.radonc.2025.110932_b0040","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/2326-6066.CIR-17-0040","article-title":"Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment","volume":"5","author":"Muroyama","year":"2017","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.radonc.2025.110932_b0045","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2023.09.020","article-title":"Dynamic Responses of Circulating T Cells After Stereotactic Body Radiation Therapy for Bone Metastasis in Patients With Breast Cancer","volume":"118","author":"Jeon","year":"2024","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110932_b0050","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.radonc.2025.110932_b0055","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","article-title":"Checkpoint Inhibitors in Combination with Stereotactic Body Radiotherapy in Patients with Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial","volume":"9","author":"Spaas","year":"2023","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.radonc.2025.110932_b0060","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-22-0622","article-title":"A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer","volume":"28","author":"Sun","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.radonc.2025.110932_b0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.radonc.2025.110932_b0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004711","article-title":"TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy","volume":"10","author":"Chiang","year":"2022","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.radonc.2025.110932_b0075","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.radonc.2025.110932_b0080","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2025.110932_b0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.canlet.2020.11.035","article-title":"TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer","volume":"499","author":"Han","year":"2021","journal-title":"Cancer Letters"},{"key":"10.1016\/j.radonc.2025.110932_b0090","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: A promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.radonc.2025.110932_b0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/cancers14010221","article-title":"High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses","volume":"14","author":"Barsoumian","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.110932_b0100","first-page":"1","article-title":"Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients","volume":"13","author":"Liu","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/j.radonc.2025.110932_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110480","article-title":"In vitro-irradiated cancer vaccine enhances anti-tumor efficacy of radiotherapy and PD-L1 blockade in a syngeneic murine breast cancer model","volume":"200","author":"Kim","year":"2024","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2025.110932_b0110","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejca.2021.08.029","article-title":"PI3K\u03b3\u03b4 inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model","volume":"157","author":"Han","year":"2021","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.radonc.2025.110932_b0115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.radonc.2025.110932_b0120","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.radonc.2025.110932_b0125","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.radonc.2025.110932_b0130","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1172\/JCI81187","article-title":"TIGIT predominantly regulates the immune response via regulatory T cells","volume":"125","author":"Kurtulus","year":"2015","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.radonc.2025.110932_b0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00262-022-03227-z","article-title":"TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism","volume":"72","author":"Zhao","year":"2023","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.radonc.2025.110932_b0140","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41423-023-00978-2","article-title":"CD8+ CD226high T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery","volume":"20","author":"Viot","year":"2023","journal-title":"Cellular & Molecular Immunology"},{"key":"10.1016\/j.radonc.2025.110932_b0145","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/2326-6066.CIR-19-0877","article-title":"CD226hiCD8+T cells are a prerequisite for anti-TIGIT immunotherapy","volume":"8","author":"Jin","year":"2020","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.radonc.2025.110932_b0150","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.radonc.2025.110932_b0155","doi-asserted-by":"crossref","unstructured":"Rudin CM, Liu S V., Lu S, Soo RA, Hong MH, Lee J-S, et al. SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung ca. J Clin Oncol 2022;40:LBA8507\u2013LBA8507. doi: 10.1200\/jco.2022.40.17_suppl.lba8507.","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA8507"},{"key":"10.1016\/j.radonc.2025.110932_b0160","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.radonc.2025.110932_b0165","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nature Immunology"},{"key":"10.1016\/j.radonc.2025.110932_b0170","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn6173","article-title":"PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance","volume":"8","author":"van Gulijk","year":"2023","journal-title":"Science Immunology"},{"key":"10.1016\/j.radonc.2025.110932_b0175","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000826","article-title":"Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer","volume":"8","author":"Ji","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.radonc.2025.110932_b0180","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.radonc.2025.110932_b0185","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124427","article-title":"TIGIT signaling restores suppressor function of Th1 Tregs","volume":"4","author":"Lucca","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.radonc.2025.110932_b0190","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","article-title":"Blockade of TIGIT\/CD155 signaling reverses t-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma","volume":"7","author":"Wu","year":"2019","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.radonc.2025.110932_b0195","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells","volume":"627","author":"Guan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2025.110932_b0200","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.radonc.2025.110932_b0205","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: One-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.radonc.2025.110932_b0210","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/sciimmunol.abg0117","article-title":"Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses","volume":"6","author":"Wei","year":"2021","journal-title":"Science Immunology"},{"key":"10.1016\/j.radonc.2025.110932_b0215","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2217735","article-title":"Studying TIGIT activity against tumors through the generation of knockout mice","volume":"12","author":"Rishiq","year":"2023","journal-title":"Oncoimmunology"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025002270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025002270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:59:04Z","timestamp":1753775944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025002270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":43,"alternative-id":["S0167814025002270"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110932","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TIGIT blockade increases efficacy of PD-1 blockade combined with radiation therapy in triple-negative breast cancer model","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110932"}}